Inventiva (NASDAQ:IVA) Coverage Initiated at UBS Group

UBS Group initiated coverage on shares of Inventiva (NASDAQ:IVA) in a report issued on Tuesday, Marketbeat reports. The firm issued a neutral rating and a $3.00 price objective on the stock.

IVA has been the subject of several other reports. HC Wainwright decreased their price target on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, October 15th. Stifel Nicolaus reduced their target price on shares of Inventiva from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

Inventiva Stock Performance

Shares of IVA stock traded up $0.03 during trading on Tuesday, hitting $2.69. 4,437 shares of the company were exchanged, compared to its average volume of 77,337. The business’s 50-day simple moving average is $2.32 and its 200 day simple moving average is $2.68. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.75.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new stake in shares of Inventiva S.A. (NASDAQ:IVA) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.